{"nctId":"NCT01863758","briefTitle":"Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A","startDateStruct":{"date":"2013-08"},"conditions":["Severe Haemophilia A"],"count":66,"armGroups":[{"label":"Human-cl rhFVIII","type":"EXPERIMENTAL","interventionNames":["Biological: Human-cl rhFVIII"]}],"interventions":[{"name":"Human-cl rhFVIII","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Severe haemophilia A (FVIII:C \\< 1%) according to medical history.\n* Male patients ≥ 18 years old.\n* Previous treatment with a FVIII concentrate (regular prophylaxis with good compliance or on-demand treatment) for at least 150 exposure days (EDs).\n* Good documentation regarding dosing and bleeding frequency in the 6 months preceding study start.\n* Immunocompetence (CD4+ count \\> 200/microliter).\n* HIV-negative, if positive, viral load \\< 200 particles/microliter or \\< 400,000 copies/mL.\n* Freely given written informed consent\n\nExclusion Criteria:\n\n* Any coagulation disorder other than haemophilia A.\n* Present or past FVIII inhibitor activity (\\> 0.6 Bethesda Unit \\[BU\\])\n* Severe liver or kidney disease.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Number of Bleeding Episodes (BE) in Phase II","description":"The annualized number of total BEs was calculated for each participant as follows: d\\*y/t, where y = the number of BEs documented in Phase II, t = the number of treatment periods in days, and d = 365.25, the number of days per year. A bleeding episode (BE) was defined as any BE whether treated or not during Phase II of the study; BEs related to surgery were not included. This study was considered as showing efficacy if the annualized number of BEs was reduced by 50% compared to the number of BEs observed in study GENA-01 where patient where severe Hemophilia A patients were treated on-demand (NCT00989196).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.05","spread":"13.43"}]}]}]},{"type":"SECONDARY","title":"Annualized Number of Spontaneous Bleeding Episodes (BE) in Phase II","description":"The annualized number of spontaneous BEs was calculated for each participant as follows: d\\*y/t, where y = the number of spontaneous BEs documented in Phase II, t = the number of treatment periods in days, and d = 365.25, the number of days per year. A spontaneous bleeding episode (BE) was defined as a BE whether treated or not during Phase II of the study. BEs related to surgery and BEs due to trauma or due to other causes were not included.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":"8.81"}]}]}]},{"type":"SECONDARY","title":"Annualized Number of Bleeding Episodes (BE) in Phase II in Participants With ≤ 2 Treatments/Week","description":"The annualized number of BEs was calculated for each participant as follows: d\\*y/t, where y = the number of BEs documented in Phase II, t = the number of treatment periods in days, and d = 365.25, the number of days per year. A bleeding episode (BE) was defined as a BE whether treated or not during Phase II of the study. BEs related to surgery were not included.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"17.4"}]}]}]},{"type":"SECONDARY","title":"Median Dosing Interval During Individually Tailored Prophylaxis","description":"The median time between 2 prophylactic doses of Human-cl rhFVIII in the prophylactic treatment phase II were determined per patient","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Dosage Per Week in Phase II","description":"The mean dosage per week during Phase II of the study are reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":"23.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":66},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Tonsillitis","Back pain"]}}}